Three things to know:
1. Varian Medical will acquire Oncozene, Embozene and Embozene Tandem, Boston Scientific’s products that treat arteriovenous malformations in the brain and spine.
2. The three products accumulated $21.2 million in sales in 2018.
3. The deal will be completed after Boston Scientific finalizes the acquisition of BTG, expected in August.
More articles on devices:
8 leadership changes in spine, orthopedic device companies in June
Fusion Robotics to advance spinal robotic devices
Alexion drug receives FDA approval for rare autoimmune disease of spinal cord
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
